EGFR and non-small cell lung carcinoma: Consequently, SELECT, a single-arm phase II study, evaluated adjuvant erlotinib for Stage IA–IIIA EGFR-positive NSCLC patients with 2-year DFS of 88% compared to the historical control of 76% from previous cohort data at Memorial Sloan Kettering (P = 0.047) [66, 67].